

## 2.2 Neoadjuvant Treatment Other

Patient ID

(Use a short abbreviation of the centre as a prefix and an anonymised numeric patient ID (e.g. MMCI-001).)

### Anthracyclines-Cyclophosphamide Treatment

Date of first administration of  
Anthracyclines-Cyclophosphamide

Date of last administration of  
Anthracyclines-Cyclophosphamide

Time from diagnosis to first administration of  
Anthracyclines-Cyclophosphamide (derived)

(Number of days between diagnosis and start date of  
anthracyclines-cyclophosphamide.)

Duration of Anthracyclines-Cyclophosphamide treatment  
(derived)

(Number of days between start of  
anthracyclines-cyclophosphamide and last  
administration of anthracyclines-cyclophosphamide.)

Time from diagnosis to first administration of  
Anthracyclines-Cyclophosphamide

(Number of days between diagnosis and start date of  
anthracyclines-cyclophosphamide.)

Duration of Anthracyclines-Cyclophosphamide treatment

(Number of days between start of  
anthracyclines-cyclophosphamide and last  
administration of anthracyclines-cyclophosphamide.)

Number of Anthracyclines-Cyclophosphamide Cycles

Total Cumulative Dose of Doxorubicin

(Values in milligrams per square meter (mg/m<sup>2</sup>).)

Total Cumulative Dose of Epirubicin

(Values in milligrams per square meter (mg/m<sup>2</sup>).)

Total Cumulative Dose of Cyclophosphamide

(Values in milligrams per square meter (mg/m<sup>2</sup>).)

Other Neoadjuvant Treatment		
	NOT received	Received
Neoadjuvant Carboplatin	<input type="radio"/>	<input type="radio"/>
Neoadjuvant Trastuzumab without Pertuzumab	<input type="radio"/>	<input type="radio"/>
Neoadjuvant Trastuzumab with Pertuzumab	<input type="radio"/>	<input type="radio"/>